Trade Leap Therapeutics, Inc. - LPTX CFD
Add to favourite- Summary
- Historical Data
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 3.16 |
Open | 3.2 |
1-Year Change | 720.51% |
Day's Range | 3.05 - 3.25 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 23, 2024 | 3.16 | 0.00 | 0.00% | 3.16 | 3.25 | 3.07 |
Apr 22, 2024 | 3.15 | 0.32 | 11.31% | 2.83 | 3.22 | 2.82 |
Apr 19, 2024 | 2.78 | -0.15 | -5.12% | 2.93 | 2.95 | 2.73 |
Apr 18, 2024 | 2.94 | 0.01 | 0.34% | 2.93 | 2.97 | 2.85 |
Apr 17, 2024 | 2.94 | 0.04 | 1.38% | 2.90 | 3.05 | 2.85 |
Apr 16, 2024 | 2.96 | -0.11 | -3.58% | 3.07 | 3.12 | 2.88 |
Apr 15, 2024 | 2.98 | -0.26 | -8.02% | 3.24 | 3.42 | 2.72 |
Apr 12, 2024 | 3.22 | 0.14 | 4.55% | 3.08 | 3.45 | 3.03 |
Apr 11, 2024 | 3.08 | -0.40 | -11.49% | 3.48 | 4.32 | 2.94 |
Apr 10, 2024 | 3.01 | -0.19 | -5.94% | 3.20 | 3.33 | 2.88 |
Apr 9, 2024 | 3.38 | 0.83 | 32.55% | 2.55 | 3.54 | 2.54 |
Apr 8, 2024 | 2.55 | 0.07 | 2.82% | 2.48 | 2.60 | 2.46 |
Apr 5, 2024 | 2.53 | 0.06 | 2.43% | 2.47 | 2.53 | 2.43 |
Apr 4, 2024 | 2.46 | -0.03 | -1.20% | 2.49 | 2.62 | 2.39 |
Apr 3, 2024 | 2.48 | -0.05 | -1.98% | 2.53 | 2.55 | 2.41 |
Apr 2, 2024 | 2.57 | -0.05 | -1.91% | 2.62 | 2.65 | 2.53 |
Apr 1, 2024 | 2.70 | 0.06 | 2.27% | 2.64 | 2.71 | 2.50 |
Mar 28, 2024 | 2.64 | -0.12 | -4.35% | 2.76 | 2.92 | 2.61 |
Mar 27, 2024 | 2.76 | 0.30 | 12.20% | 2.46 | 2.78 | 2.36 |
Mar 26, 2024 | 2.46 | 0.06 | 2.50% | 2.40 | 2.47 | 2.38 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Leap Therapeutics, Inc. Company profile
About Leap Therapeutics Inc
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models. TRX518 is a humanized anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody designed for the immune system’s anti-tumor response as an immune checkpoint agonist.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Leap Therapeutics Inc revenues remained flat at $1.5M. Net loss applicable to common stockholders increased 8% to $40.6M. Revenues reflect market conditions. Higher net loss reflects Research and development - Balancing va increase of 57% to $30.5M (expense), Foreign currency gains (losses) decrease from $738K (income) to $379K (expense).
Industry: | Bio Therapeutic Drugs |
47 Thorndike St Ste B1-1
CAMBRIDGE
MASSACHUSETTS 02142-1799
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com